Treatment data for triple-negative breast cancer show the importance of macrophage subtypes and cancer-cell metaprograms for interferon signalling, HLA expression and cell cycle activity that are associated with a good response to neoadjuvant chemotherapy.
Study participant details from the ARTEMIS Trial
The clinical trial protocol was reviewed and approved by The University of Texas MD Anderson Cancer Center Institutional Review Board and all partici… [+43352 chars]
The clinical trial protocol was reviewed and approved by The University of Texas MD Anderson Cancer Center Institutional Review Board and all partici… [+43352 chars]